HC Wainwright & Co. Reiterates Buy on Checkpoint Therapeutics, Maintains $34 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Checkpoint Therapeutics (NASDAQ:CKPT) and maintained a $34 price target.
June 24, 2024 | 5:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Checkpoint Therapeutics and maintained a $34 price target.
The reiteration of a Buy rating and the maintenance of a $34 price target by a reputable analyst can boost investor confidence in Checkpoint Therapeutics, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100